GNbAC1

Drug Profile

GNbAC1

Alternative Names: GENHP-01; GNN001

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeNeuro
  • Class Antihyperglycaemics; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Toll-like receptor 4 antagonists; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 1 diabetes mellitus
  • Phase I Chronic inflammatory demyelinating polyradiculoneuropathy

Most Recent Events

  • 13 Apr 2018 Phase-I clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (IV) (GeNeuro pipeline, April 2018)
  • 26 Mar 2018 12-month adverse events and efficacy data from the phase II CHANGE-MS trial in Multiple sclerosis released by GeNeuro and Servier
  • 22 Feb 2018 GNbAC1 receives Orphan Drug status for Chronic inflammatory demyelinating polyradiculoneuropathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top